Using the PD-L1 inhibitor durvalumab with neoadjuvant cisplatin/gemcitabine chemotherapy and continuing using it as adjuvant therapy after radical surgery could achieve high rates of event-free survival and downstaging, new findings show.
In a study, patients undergoing thrice-weekly extended home hemodialysis had a lower death risk compared with those receiving in-center conventional hemodialysis.